Search - tctmd.com

Displaying 321 - 340 of 343

Sort: Relevancy | Date

News Industry News

U.S. FDA Accepts Filing of Cardiovascular Outcomes Data for Jardiance® (empagliflozin)

January 24, 2016

News Conference News ESC 2015

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

September 09, 2015

News Conference News ESC 2015

Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes

Yael L. Maxwell

September 01, 2015

News Conference News ESC 2015

TECOS: No Differences in Heart Failure Outcomes When Sitagliptin Added to Usual Care in Diabetics

Yael L. Maxwell

August 31, 2015

News Industry News

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

August 20, 2015

News Industry News

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

August 20, 2015

News Daily News

新型反义抑制剂能够降低高甘油三酯水平

August 13, 2015

News Daily News

Un Nuevo Inhibidor Antisentido Reduce los Niveles Altos de Triglicéridos

August 13, 2015

News Daily News

Novel Antisense Inhibitor Cuts High Triglyceride Levels

August 13, 2015

News Daily News

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

Yael L. Maxwell

August 12, 2015

News Industry News

Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions

June 05, 2015

News Daily News

Vorapaxar es Eficaz como Prevención Secundaria en Pacientes Diabéticos con Antecedentes de IM

L.A. McKeown

February 22, 2015

News Daily News

Vorapaxar Effective for Secondary Prevention in Diabetic Patients With Prior MI

L.A. McKeown

February 22, 2015

News Daily News

CREDO-Kyoto: Diabetic Patients With 3-Vessel or Left Main Disease Fare Better With CABG

February 08, 2015

News Daily News

Studies Explore Impact of Diabetes on Platelet Reactivity in Clopidogrel-Treated PCI Patients

October 10, 2014

News Daily News

PCI, Surgery Show Similar Long-term Mortality in Diabetic, Nondiabetic Patients

L.A. McKeown

August 15, 2012

News Daily News

Meta-analysis: Early Invasive Strategy Best for Diabetic Patients with NSTE ACS

July 03, 2012

News Daily News

Better Clopidogrel Response Seen with Increased Smoking Levels

Jason Kahn

March 21, 2012

News Daily News

HORIZONS-AMI: Bivalirudin Reduces Cardiac Death in Diabetics

Jason Kahn

July 18, 2011

Advertisement

U.S. FDA Accepts Filing of Cardiovascular Outcomes Data for Jardiance® (empagliflozin)

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes

TECOS: No Differences in Heart Failure Outcomes When Sitagliptin Added to Usual Care in Diabetics

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

新型反义抑制剂能够降低高甘油三酯水平

Un Nuevo Inhibidor Antisentido Reduce los Niveles Altos de Triglicéridos

Novel Antisense Inhibitor Cuts High Triglyceride Levels

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions

Vorapaxar es Eficaz como Prevención Secundaria en Pacientes Diabéticos con Antecedentes de IM

Vorapaxar Effective for Secondary Prevention in Diabetic Patients With Prior MI

CREDO-Kyoto: Diabetic Patients With 3-Vessel or Left Main Disease Fare Better With CABG

Studies Explore Impact of Diabetes on Platelet Reactivity in Clopidogrel-Treated PCI Patients

PCI, Surgery Show Similar Long-term Mortality in Diabetic, Nondiabetic Patients

Meta-analysis: Early Invasive Strategy Best for Diabetic Patients with NSTE ACS

Better Clopidogrel Response Seen with Increased Smoking Levels

HORIZONS-AMI: Bivalirudin Reduces Cardiac Death in Diabetics

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content